Banco Santander S.A. lifted its position in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 20.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,638 shares of the company’s stock after buying an additional 8,458 shares during the quarter. Banco Santander S.A.’s holdings in Novo Nordisk A/S were worth $5,624,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the company. MML Investors Services LLC raised its stake in Novo Nordisk A/S by 6.2% in the fourth quarter. MML Investors Services LLC now owns 42,938 shares of the company’s stock valued at $4,809,000 after purchasing an additional 2,509 shares in the last quarter. Benjamin Edwards Inc. bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $47,000. Westwood Holdings Group Inc. grew its position in Novo Nordisk A/S by 75.8% during the fourth quarter. Westwood Holdings Group Inc. now owns 13,282 shares of the company’s stock valued at $1,487,000 after acquiring an additional 5,726 shares during the last quarter. Ipswich Investment Management Co. Inc. grew its position in Novo Nordisk A/S by 1.4% during the first quarter. Ipswich Investment Management Co. Inc. now owns 52,380 shares of the company’s stock valued at $5,817,000 after acquiring an additional 710 shares during the last quarter. Finally, Cornerstone Advisory LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $28,000.
Wall Street Analyst Weigh In
A number of research analysts have commented on NVO shares. Cowen upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Monday, April 25th. BNP Paribas upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $750.00 price target on the stock in a research report on Monday, June 27th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday, July 15th. UBS Group cut shares of Novo Nordisk A/S from a “neutral” rating to a “sell” rating in a research report on Tuesday, June 28th. Finally, Bryan, Garnier & Co upgraded shares of Novo Nordisk A/S from a “sell” rating to a “neutral” rating in a report on Thursday, May 5th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $682.43.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S Cuts Dividend
The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 23rd. Investors of record on Monday, August 15th will be issued a $0.5836 dividend. This represents a yield of 1.1%. The ex-dividend date is Friday, August 12th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 44.18%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.